Search

Designed for practicing ophthalmologists, Eye Insights provides practical and relevant best practice information from Mass. Eye and Ear specialists in an easy-to-read format. Published twice a year, this clinical newsletter is mailed to 18,000 practicing ophthalmologists nationwide and features a...

While significant progress has been achieved in treating retinal diseases, researchers at Mass. Eye and Ear/Schepens Eye Research Institute remain deeply committed to improving current therapies, refining diagnostic tools, and developing new therapies that leverage advances in biotechnology and...

A Revolutionary Technology Dr. Claes H. Dohlman’s most notable achievement is the Boston Keratoprosthesis (KPro), a collar button design keratoprosthesis composed of a front plate with a stem, which houses the optical portion of the device, and a back plate with a slit. Available in Type I and Type...

Advances in postoperative care have greatly improved the clinical success of the Boston KPro. Common complications such as inflammation and infection are significantly lower with today’s prophylactic drug regimens. Innovative devices have also improved postoperative management of KPro. Soft contact...

Epidemiology The annual incidence of open-globe injuries worldwide is estimated to be 203,000 cases. Overall, males comprise approximately 80 percent of open-globe injuries. Males age 10 to 30 are at greatest risk. The chance of blunt globe rupture also increases after some types of ocular surgical...

Algorithm guides treatment of bacterial keratitis, reduces costs Culturing all suspected cases of bacterial eye infection can be costly, time consuming, and often unnecessary. A new algorithm developed at Mass. Eye and Ear, consisting of a simple set of rules, now helps clinicians in the Emergency...

Do these patients sound familiar? “I’ve worn glasses and contacts for years. My ophthalmologist never mentioned LASIK could be another option.” “Ten years ago, one of my friends had LASIK and she ended up with severe dry eye. I’m not sure I’d want to take the risk.” Precision technology enhances...

Dear Colleagues, Research in gene augmentation and genome editing for the treatment of inherited retinal disorders (IRDs) is thriving. It is estimated that IRDs affect about 200,000- 300,000 people in the United States and 4-6 million people worldwide. Most patients with these conditions become...

Gene-Augmentation Therapy Gene therapy typically refers to gene-augmentation therapy. In this approach, a healthy version of the mutated gene is packaged inside an engineered and nonpathogenic form of adeno-associated virus (AAV), with the virus serving as a vector to carry the gene. AAV does not...

Advances in the future may include viral vectors, non-viral vectors, and delivery methods that allow treatment of a greater retinal expanse and an expanded approach to technical challenges related to gene size and disease mechanisms. Genetic therapies for non-retinal ophthalmic diseases are also...